For GLP-1 agonists, after LEADER and SUSTAIN-6 trials having demonstrated a reduction in CV mortality but not heart failure hospitalization [41, 42], subsequent FIGHT and LIVE trials also failed to show improvement in heart failure endpoints [43, 44]. The gene discussed is GCG; the disease is heart failure.